Since the introduction of effective antiretroviral therapy for human immunodeficiency virus (HIV), adverse events related to liver disease have become important causes of morbidity and mortality in patients coinfected with HIV and hepatitis C virus (HCV). Coinfected patients progress more quickly to fibrosis and cirrhosis compared to those infected only with HCV [1] , and several studies suggest that liver-related complications, such as hepatocellular carcinoma (HCC), also occur more rapidly in the coinfected population [2] [3] [4] . HCC accounts for an increasing proportion of liver-related deaths in HIV/HCVcoinfected patients [5] , and thus strategies to decrease HCCrelated morbidity and mortality are needed.
Given that early detection has been shown to improve outcomes, screening for HCC has been studied in various highrisk groups. One prospective randomized trial in hepatitis B virus infection and several observational studies of patients with HCV have shown that screening confers a survival benefit [6] [7] [8] . Thus, organizations in Europe and North America recommend screening for HCC in HCV-infected patients with cirrhosis. The American Association for the Study of Liver Diseases suggests screening using ultrasonography every 6-12 months [9] , and the European Association for the Study of the Liver recommends surveillance every 6 months [10] .
It is not known to what extent these recommendations for HCC screening are followed in the complex coinfected population where there may be logistic barriers to screening. We examined the frequency of ultrasonography use in coinfected patients with cirrhosis followed in a prospective cohort.
METHODS

Study Design
The Canadian HIV/HCV Co-infection Cohort is a prospective multicenter study, enrolling adults aged >16 years from 16 centers across Canada with documented HIV infection and serologic evidence of HCV exposure on the basis of antibody positivity as previously described [11] . After informed consent, patients underwent an initial evaluation and then follow-up visits approximately every 6 months, where information was collected on disease-related testing and events that had occurred since the previous visit.
Study Population
Nine hundred fifty-two HIV/HCV-coinfected patients with a minimum of 6 months of follow-up between March 2003 and October 2012 were assessed. At baseline and at each follow-up visit, patients were categorized as having documented cirrhosis if they had compatible histology on a liver biopsy or documented end-stage liver disease (ascites, esophageal varices, spontaneous bacterial peritonitis, or hepatic encephalopathy) captured using specific case report forms. Patients without documented cirrhosis were categorized as having possible cirrhosis retrospectively using laboratory markers of hepatic dysfunction collected during study visits: total bilirubin ≥85.5 µmol/L, albumin <20 g/L, international normalized ratio >1.7, or aspartate aminotransferase (AST) to platelet ratio index (APRI) >2.0 (APRI = [AST value/upper limit of normal of AST]/platelet count × 100). These values were chosen as they have previously been validated to identify those at risk of hepatic decompensation [12] . The aim of evaluating this second group was to assess screening among patients who might not have been reported as having cirrhosis but could be at risk for HCC. Patients were followed until October 2012 or censored at death or at their last visit, if lost to follow-up.
Screening
Information on whether an abdominal ultrasound was done for each patient was collected by research personnel during study visits. Radiology reports were requested from individual centers and reviewed. Ultrasounds were considered as possible screening tests if they were performed after the visit where a patient was diagnosed with documented or possible cirrhosis.
Analysis
Time zero for the analyses was the date at which a clinical diagnosis of documented cirrhosis was first reported or the date that laboratory tests first indicated probable cirrhosis. All screening tests done after these respective dates were totaled for each patient and the mean/median number of ultrasounds per patient per year postdiagnosis was calculated. Multivariate Cox regression analysis was used to evaluate factors associated with time to the first screening ultrasound postdiagnosis. We included covariates that had statistically significant hazard ratios (HRs) in univariate analyses as well as variables that were determined a priori to be clinically important. Final models were adjusted for age, sex, alcohol use, active injection drug use, income, antiretroviral therapy, HIV RNA, and study center grouped according to type of screening process used (standard protocol/automated reminder vs at provider's discretion). All analyses were conducted using R program for Windows Release 2.11.1 (R cran, Auckland, New Zealand).
RESULTS
We identified 144 patients with documented and 220 patients with possible cirrhosis who met inclusion criteria for the 2 mutually exclusive groups. The baseline characteristics of the 2 groups were similar to those without cirrhosis except as expected for longer duration of HCV infection, higher APRI scores, and higher rate of HCV treatments (Table 1) .
Among patients with documented cirrhosis, 52 (36%) never had an abdominal ultrasound performed during study followup (median follow-up, 2.5 years; interquartile range [IQR], 1.2-3.9). The mean number of ultrasounds per patient per year was 0.6 (median, 0.4; IQR, 0-0.9) for this group overall and 0.9 (median, 0.7; IQR, 0.4-1.3) for those who had at least 1 screening ultrasound. In the group with possible cirrhosis, 109 (49.5%) did not have an abdominal ultrasound (median followup, 2.4 years; IQR, 1.0-3.7), and the mean number of ultrasounds per patient per year was 0.4 (median, 0.1; IQR, 0-0.5) overall and 0.7 (median, 0.5; IQR, 0.3-0.9) for those who had at least 1 screening ultrasound. There were 9 incident diagnoses of HCC, 2 of which occurred in patients without any documented abdominal ultrasound prior to diagnosis. HCC was screeningdetected in 2 patients; for the remainder there were large gaps in screening between the last ultrasound and HCC diagnosis. Mortality among patients with HCC was 69%.
Results of univariate and multivariate analyses are shown in Table 2 . Among patients with documented cirrhosis, factors that were associated with not having an ultrasound in follow-up were lower monthly income and active injection drug use at diagnosis of cirrhosis, whereas alcohol users and patients on ART were more likely to be screened. There was considerable variability across the centers with respect to likelihood of performing screening. Patients who were followed at centers with standardized systems to track or refer patients for screening were far more likely to have had an ultrasound performed. In multivariate analyses, the only factor that remained significantly associated with having had an ultrasound was the presence of a systematic screening system. This was also the case for those with possible cirrhosis.
DISCUSSION
In this cohort of HIV/HCV-coinfected patients, more than onethird of patients with documented or possible cirrhosis did not undergo appropriate screening for HCC with ultrasonography during the course of their follow-up. The infrequent performance of ultrasounds in the group with possible cirrhosis in particular suggests that patients at risk for advanced liver disease may not be recognized and diagnosed as such.
The frequency of abdominal ultrasounds among those screened was also lower than guidelines recommend, at <1 per year. The proportion that failed to be screened is somewhat higher than that in a recent study in HCV-infected veterans with cirrhosis, where no HCC surveillance was done for 29.5% of patients, and routine surveillance for only 12.0% [13] . In addition, 2 of 9 patients diagnosed with HCC during the course of our study did not have a documented abdominal ultrasound prior to diagnosis, suggesting missed opportunities for detecting HCC.
Although HCC screening is recommended by American, Canadian, and European guidelines, there are many factors that may impede regular ultrasonography. Given the importance of virologic control of HIV and treatment of HCV, medical visits may be focused more on management of these infections, as opposed to consequences of liver disease. The strongest predictor of having had screening was the presence of a systematic process in place to schedule and follow screening ultrasounds, usually with the involvement of a hepatologist. There also may be patient-related social barriers to care that make regular testing a challenge. Low income was associated with a lower likelihood of being screened. Thus, despite universal access to healthcare in this cohort, socioeconomic concerns, such as absenteeism from work or childcare costs, may have impacted ancillary healthcare follow-up. As the effect of income was attenuated in models that accounted for the presence of systematic screening systems, an alternate explanation may be that lower-income patients frequent centers that are less likely to have specialists and systematic screening methods in place. Interestingly, alcohol use also seemed to be associated with a higher likelihood of having an ultrasound, suggesting these patients may be perceived by clinicians to be at higher risk for advanced liver disease or related complications.
There were several limitations to this study. Although abdominal ultrasounds were presumed to have been performed for the purpose of HCC screening, information on the reason for ordering ultrasounds was not collected. Thus, some of the ultrasounds ordered may have been done for other reasons, and we may have overestimated the number done for screening purposes. We collected information only on ultrasounds that were performed, not those that were requested, so we cannot determine if physicians in fact intended to screen but patients did not present for their tests. Differentiating between these 2 scenarios would be important to better understand interventions that might be put in place to improve screening for this population.
Given that HCC is a cause of substantial morbidity and mortality in the coinfected population, methods to improve compliance with screening, such as patient and healthcare worker education, financial support to attend visits, and appropriate radiologic infrastructure should be explored to reduce the impact of HCC in the coinfected population. Patient care protocols with automated reminders may be a particularly effective means of ensuring compliance with screening.
Notes
